Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABSK112 · 1 trial · 1 indication
Dose-limiting toxicities
Adverse events
Adverse events of special interest (AESIs)
Serious adverse events (SAEs)
| Arm | Type | Description |
|---|---|---|
| ABSK112 | EXPERIMENTAL | During the escalation part, the administration of oral ABSK112 will be guided by Bayesian optimal interval (BOIN) design based on safety data collected until a maximum tolerated dose (MTD) has been identified. The first dose level will be administered as QD, and different dosing frequencies (e.g., BID) may be explored in subsequent doses depending on emerging safety and pharmacokinetic data. A separate food effect cohort may be conducted. In expansion part, patients will be treated at the selected RDE dose level. |
| Name | Type | Description |
|---|---|---|
| ABSK112 | DRUG | In the escalation part, patients will receive a single dose of oral ABSK112 on Cycle1 Day1 only, and then patients will continuously receive ABSK112 once daily (QD) or twice daily (BID) in subsequent cycles. In the expansion part, patients will each be treated at the selected RDE dose level. |
Inclusion Criteria: 1. Patients should understand, sign, and date the written informed consent form prior to screening. 2. Male or female aged 18 years or older. 3. Patients with histologically or cytologically confirmed locally advanced (and not a candidate for definitive therapy) or metastatic NS...
Top 20 of 84 competitors
ABSK112 is an investigational small molecule being developed for the treatment of Non-Small Cell Lung Cancer (NSCLC). It is currently in Phase 1 clinical development, meaning it is still being studied for safety, tolerability, and pharmacokinetics in patients with this condition.
ABSK112 is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker symbol YCBD. The company is conducting a Phase 1 clinical trial of ABSK112 in patients with Non-Small Cell Lung Cancer.
ABSK112 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The ongoing Phase 1 trial is recruiting patients to evaluate the safety, tolerability, and pharmacokinetics of ABSK112 in Non-Small Cell Lung Cancer.
ABSK112 is being studied in one active clinical trial, identified as NCT06225804. This Phase 1 study is assessing the safety, tolerability, and pharmacokinetics of ABSK112 in patients with Non-Small Cell Lung Cancer. The trial is recruiting participants in the United States and China, with a target enrollment of 164 patients.
ABSK112 is a distinct investigational drug candidate. No alternative names for ABSK112 have been reported. It is being developed as a small molecule for Non-Small Cell Lung Cancer and is currently in Phase 1 clinical trials.